Townsquare Capital LLC Buys 6,249 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Townsquare Capital LLC grew its stake in Prestige Consumer Healthcare Inc. (NYSE:PBHFree Report) by 8.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,168 shares of the company’s stock after acquiring an additional 6,249 shares during the period. Townsquare Capital LLC’s holdings in Prestige Consumer Healthcare were worth $5,564,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PBH. Opal Wealth Advisors LLC bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $26,000. Quest Partners LLC lifted its stake in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $35,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PBH shares. DA Davidson reiterated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

View Our Latest Research Report on PBH

Prestige Consumer Healthcare Stock Up 1.2 %

NYSE PBH opened at $84.17 on Friday. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 20.48, a PEG ratio of 2.38 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $86.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The company has a 50 day moving average of $75.17 and a 200-day moving average of $71.06.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the company posted $1.07 EPS. The company’s revenue was down .9% compared to the same quarter last year. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. Corporate insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

(Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBHFree Report).

Institutional Ownership by Quarter for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.